SAN DIEGO, June 20, 2023 (GLOBE NEWSWIRE) — ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to…Original Article
ARS Pharmaceuticals Announces PDUFA Date Extension for neffy® (epinephrine) for the Treatment of Allergic Reactions (Type 1), Including Anaphylaxis
